{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"}]}],"title":"Threshold: 10^5"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.63","upperLimit":"80.59","value":"25.0"}]}],"title":"Threshold: 10^6"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"MRD negativity rate was defined as percentage of participants with CR or sCR with negative MRD per IMWG sequencing criteria by bone marrow aspirate (BMA). sCR: CR and normal sFLC ratio with absence of clonal cells in BMB/BMA by immunohistochemistry, immunofluorescence or flow cytometry.CR: negative immunofixation on serum and urine, disappearance of soft tissue plasmacytoma and \\<5% plasma cells in BMA, if disease measured by sFLC only, preceding criteria plus normal sFLC ratio. MRD was reported at threshold frequency of 10\\^5 and 10\\^6.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"NUMBER","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From date of first dose until confirmed disease progression, death, start of new anticancer therapy, whichever occurred first (maximum of 65.1 weeks of treatment)","title":"Minimal Residual Disease (MRD) Negativity Rate","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}